Milestone Pharmaceuticals Announces $80 Million Private Financing
MONTREAL and CHARLOTTE, N.C., Oct. 25, 2018 — Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing interventions for tachycardias, today announced the completion of an $80 million private financing. The equity financing included the support of new and existing institutional investors. Among new investors were RTW Investments, LP, who led the round, Venrock Healthcare Capital Partners, and Boxer Capital of Tavistock Group. Existing investors included Novo Holdings A/S, Forbion, funds managed by Tekla Capital Management LLC, Domain Associates, BDC Capital, Pappas Capital, GO Capital, and Fonds de solidarité FTQ. This builds on the company’s prior series C financing, led by Novo Holdings, which occurred in July 2017.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.